Delcath Systems to Present at LD Micro Virtual Investor Conference on June 10, 2021, at 2:30pm ET
03. Juni 2021 09:00 ET
|
Delcath Systems, Inc.
NEW YORK, June 03, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
Delcath Systems to Present at Jefferies Virtual Healthcare Conference
26. Mai 2021 09:00 ET
|
Delcath Systems, Inc.
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
Delcath Systems, Inc. Announces First Quarter 2021 Results
11. Mai 2021 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...
Delcath Systems Schedules Conference Call to Report 2021 First Quarter Financial Results
30. April 2021 16:01 ET
|
Delcath Systems, Inc.
NEW YORK, April 30, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
Delcath Systems Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
30. April 2021 09:00 ET
|
Delcath Systems, Inc.
A Presentation of Positive Preliminary Efficacy Results from the FOCUS Phase III trial Company Q&A Webinar Scheduled for Monday, June 7, 2021 at 8:30am ET NEW YORK, April 30, 2021 ...
Delcath Systems, Inc. Announces Revised NICE Guidance for CHEMOSAT in the United Kingdom
21. April 2021 08:38 ET
|
Delcath Systems, Inc.
NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Systems, Inc. Shares Additional Information Regarding FOCUS Trial Power Calculation
31. März 2021 14:55 ET
|
Delcath Systems, Inc.
NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...
Delcath Systems, Inc. Announces Fourth Quarter 2020 Results, Highlights Preliminary Positive FOCUS Trial Results; Conference Call Today at 8:00am Eastern Time
31. März 2021 07:45 ET
|
Delcath Systems, Inc.
NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today...
Delcath Systems, Inc. Announces Positive Preliminary Results from Phase 3 FOCUS Trial of HEPZATO in Patients with Metastatic Ocular Melanoma
31. März 2021 07:30 ET
|
Delcath Systems, Inc.
Based on Preliminary Data, FOCUS Trial Achieves Prespecified Success Threshold Conference Call Today at 8:00am Eastern Time NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc....
Delcath Systems Schedules Conference Call to Report 2020 Fourth Quarter Financial Results
24. März 2021 16:01 ET
|
Delcath Systems, Inc.
NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...